Clinical trials consistently demonstrate GLP-1 agonists produce significant weight loss and improve cardiovascular outcomes in people with obesity or type 2 diabetes
Updated guidelines support referrals for evaluation for patients and clients who meet established criteria, such as higher BMI and/or weight-related conditions, especially when non-surgical approaches havent produced adequate or lasting results
Duration of treatment is based on each individual's goal, starting weight, underlying health, age, gender, response to treatment, and other factors
Plus de 10 ans avant la dcouverte de la leptine, plusieurs chercheurs, dont MM
Clinical trials have shown that Wegovy induces significantly greater weight loss compared to other anti-obesity medications, with a substantial proportion of patients achieving clinically meaningful weight reduction
Patho 101: GLP-1 receptors are found in areas of the brain involved in appetite regulation, such as the hypothalamus, and activation of these receptors can lead to decreased food intake and increased feelings of fullness
